NEOTHERAPEUTICS INC Form SC 13G July 03, 2002

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 8)

| NEOTHERAPEUTICS, INC. |
|---|
| (Name of Issuer) |
| COMMON |
| (Title of Class of Securities) |
| 640656104 |
| (CUSIP Number) |
| 06/30/02 |
| (Date of Event Which Requires Filing of this Statement) |
| Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
| [X] Rule 13d-1(b) |
| [_] Rule 13d-(c) |
| [_] Rule 13d-1(d) |
| |

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(SC13G-07/98)

12. TYPE OF REPORTING PERSON*

| CUSIP No. | 640656104 | 13G | Page | of | Pages |
|--------------------------------|---|-------------------|---------------|------------|---------------------------------------|
| | EPORTING PERSONS ENTIFICATION NO. OF AB | BOVE PERSONS (EN | TITIES ONLY) | | |
| 2. CHECK THE | APPROPRIATE BOX IF A | MEMBER OF A GRO | UP* | (a) (b) | |
| 3. SEC USE OF | NLY | | | | |
| 4. CITIZENSH NEW YORK STATE | IP OR PLACE OF ORGANIZ | ZATION | | | |
| NUMBER OF | 5. SOLE VOTING POWE | ER | | | |
| SHARES | 61,650 (Assuming ex | xercise of 14,60 | 0 warrants.) | | |
| BENEFICIALLY | 6. SHARED VOTING PC | DWER | | | |
| OWNED BY | -0- | | | | |
| EACH | 7. SOLE DISPOSITIVE | E POWER | | | · · · · · · · · · · · · · · · · · · · |
| REPORTING | 61,650 (Assuming | g exercise of 14 | ,600 warrants | .) | |
| PERSON | 8. SHARED DISPOSITI | VE POWER | | | |
| WITH | 109,270 (Assuming | exercise of 17, | 800 warrants. |) | |
| 9. AGGREGATE | AMOUNT BENEFICIALLY C | OWNED BY EACH RE | PORTING PERSO | N | |
| 170,920 (Assum | ing exercise of 32,400 |) warrants.) | | | |
| 10. CHECK BOX | IF THE AGGREGATE AMOU | JNT IN ROW (9) E. | XCLUDES CERTA | IN SHA | RES* |
| | | | | | [_] |
| 11. PERCENT O | F CLASS REPRESENTED BY | AMOUNT IN ROW | (9) | | |
| 64% (Assumin | g exercise of 32,400 w | warrants.) | | | |

*SEE INSTRUCTIONS BEFORE FILLING OUT! 13G CUSIP No. 640656104 Page of Pages Item 1(a). Name of Issuer: Neotherapeutics, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 157 Technology Drive Irvine, CA 92618 Item 2(a). Name of Person Filing: Ingalls & Snyder LLC Item 2(b). Address of Principal Business Office, or if None, Residence: 61 Broadway New York, NY 10006 Item 2(c). Citizenship: New York State LLC Item 2(d). Title of Class of Securities: COMMON Item 2(e). CUSIP Number: 640656104 If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) Item 3. or (c), Check Whether the Person Filing is a: (a) [X] Broker or dealer registered under Section 15 of the Exchange Act. (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act. (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act. [_] Investment company registered under Section 8 of the Investment Company Act.

(e) [_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f) [_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);(h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; (j) [_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). If this statement is filed pursuant to Rule 13d-1(c), check this box. [_] CUSIP No. 640656104 13G Page of Pages Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 170,920 (Assuming exercise of 32,400 warrants.) (b) Percent of class: ..64% (Assuming exercise of 32,400 warrants.) (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 61,650 (Assuming exercise of 14,600 warrants.) (ii) Shared power to vote or to direct the vote: -0-(iii) Sole power to dispose or to direct the disposition of: 61,650 (Assuming exercise of 14,600 warrants.) (iv) Shared power to dispose or to direct the disposition of: 91,470 (Assuming exercise of 17,800 warrants.) Item 5. Ownership of Five Percent or Less of a Class. Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Item 8. Identification and Classification of Members of the Group.

Item 9. Notice of Dissolution of Group.

Item 10. Certifications.

(a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1 (b):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

(b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1 (c):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

| 07/03/02 | |
|--|--|
| (Date) | |
| Ingalls & Snyder LLC by /s/ Edward H. Oberst | |
| (Signature) | |
| Edward H. Oberst Managing Director | |
| (Name/Title) | |

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 (b) for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).